FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033190176> ?p ?o ?g. }

• W3033190176 endingPage "669" @default.
• W3033190176 startingPage "669.1" @default.
• W3033190176 abstract "Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the presence of autoantibodies and a variable spectrum of clinical manifestations and disease severity. The 2019 criteria for SLE classification by the American College of Rheumatology and European League against Rheumatism define ANA positivity by immunofluorescence or by an equivalent solid-phase assay as the entry criterion (1). However, the prevalence of ANA positivity and the reliability of solid-phase assays in SLE are still a matter of controversy (2). Furthermore, the significance of ANA negativisation during follow-up is uncertain (3). Objectives: Our aim was to retrospectively analyse data on the frequency of ANA seroconversion during the follow-up in a cohort of SLE patients with renal involvement. Methods: Adult patients independent of age at SLE onset with a follow-up duration of at least 36 months starting from January 2009 (for standardization of ANA measurement) and with at least one ANA measurement per year were included in this retrospective longitudinal study. Data on demographic, clinical and laboratory characteristics of the study population are reported in table 1. ANA have been measured with Hep2 cell immunofluorescence assay. Table 1. Demographic, clinical and laboratory baseline characteristics of the 121 patients suffering from systemic lupus erythematosus (SLE). Demographics Gender, %F (n ) 93 (112) Age in years, mean±SD 41.6±12.6 Clinical features Age at SLE onset in years, mean±SD 28.0±11.9 SLE duration in years, mean±SD 13.8±9.5 SLEDAI, median (min-max ) 4 (0 – 27) Laboratory profile Serum creatinine mg/dL, median (min-max ) 0.8 (0.4 – 2) 24h urine protein g/24h, median (min-max ) 0.5 (0 – 13.8) ANA, %pos (n ) 93 (112) Anti-ENA, %pos (n ) 49 (59) Anti-dsDNA, %pos (n ) 43 (51) Results: A total of 121 SLE subjects with renal involvement were enrolled. Mean follow-up ± standard deviation (SD) was 8 ± 2 years. Ten subjects (8.3%) with positive ANA at the beginning resulted ANA negative at the end of the follow-up. These subjects had different initial ANA titres: 1:1280 (n=1), 1:640 (n=2), 1:320 (n=2), 1:160 (n=3) and 1:80 (n=2); 48 subjects (39.7%) showed a decrease in ANA titre. Of the 9 patients (7.4%) that were negative at the beginning of follow-up, 6 remained negative, whereas 3 showed ANA positivity at the end of the follow-up with ANA titres 1:160 (n=2) and 1:320 (n=1). No differences between subjects with and without ANA titre variations in terms of age (p=0.551), disease duration (p=0.786), SLEDAI at the beginning (p=0.453) and at the end of follow-up (p=0.169) were observed. ANA negativisation and titre variations at the end of follow-up did not correlate with any of the treatments taken during follow-up, including a history of cyclophosphamide (p=0.788). Conclusion: In our cohort of patients with SLE and renal involvement, 10% of patients experienced negativisation and around 40% of patients showed a decrease in ANA titre during follow-up, independent of disease characteristics and previous treatment. Further studies are warranted to clarify the underlying mechanisms and clinical significance of ANA seroconversion and titre variation in SLE patients. However, based on our results, ANA positivity seems to be a relatively stable parameter further supporting its use as an entry classification criterion for SLE. References: [1]Aringer M et al. Arthritis Rheumatol. 2019; 71(9):1400-1412. [2]Pisetsky DS et al. Autoimmun Rev. 2019; 18(12):102400. [3]Frodlund M et al. Clin Exp Immunol. 2019. Epub ahead of print. Disclosure of Interests: None declared" @default.
• W3033190176 created "2020-06-12" @default.
• W3033190176 creator A5019339083 @default.
• W3033190176 creator A5019636253 @default.
• W3033190176 creator A5045284474 @default.
• W3033190176 creator A5056105834 @default.
• W3033190176 creator A5064594935 @default.
• W3033190176 creator A5069417319 @default.
• W3033190176 date "2020-06-01" @default.
• W3033190176 modified "2023-10-06" @default.
• W3033190176 title "FRI0169 ANTINUCLEAR ANTIBODY SEROCONVERSION DURING FOLLOW-UP IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS" @default.
• W3033190176 doi "https://doi.org/10.1136/annrheumdis-2020-eular.2685" @default.
• W3033190176 hasPublicationYear "2020" @default.
• W3033190176 type Work @default.
• W3033190176 sameAs 3033190176 @default.
• W3033190176 citedByCount "0" @default.
• W3033190176 crossrefType "journal-article" @default.
• W3033190176 hasAuthorship W3033190176A5019339083 @default.
• W3033190176 hasAuthorship W3033190176A5019636253 @default.
• W3033190176 hasAuthorship W3033190176A5045284474 @default.
• W3033190176 hasAuthorship W3033190176A5056105834 @default.
• W3033190176 hasAuthorship W3033190176A5064594935 @default.
• W3033190176 hasAuthorship W3033190176A5069417319 @default.
• W3033190176 hasBestOaLocation W30331901761 @default.
• W3033190176 hasConcept C126322002 @default.
• W3033190176 hasConcept C149443304 @default.
• W3033190176 hasConcept C159654299 @default.
• W3033190176 hasConcept C163764329 @default.
• W3033190176 hasConcept C167135981 @default.
• W3033190176 hasConcept C198451711 @default.
• W3033190176 hasConcept C203014093 @default.
• W3033190176 hasConcept C2775915377 @default.
• W3033190176 hasConcept C2776670291 @default.
• W3033190176 hasConcept C2776912625 @default.
• W3033190176 hasConcept C2777489490 @default.
• W3033190176 hasConcept C2779075594 @default.
• W3033190176 hasConcept C2779134260 @default.
• W3033190176 hasConcept C2779912601 @default.
• W3033190176 hasConcept C2908647359 @default.
• W3033190176 hasConcept C71924100 @default.
• W3033190176 hasConcept C72563966 @default.
• W3033190176 hasConcept C99454951 @default.
• W3033190176 hasConceptScore W3033190176C126322002 @default.
• W3033190176 hasConceptScore W3033190176C149443304 @default.
• W3033190176 hasConceptScore W3033190176C159654299 @default.
• W3033190176 hasConceptScore W3033190176C163764329 @default.
• W3033190176 hasConceptScore W3033190176C167135981 @default.
• W3033190176 hasConceptScore W3033190176C198451711 @default.
• W3033190176 hasConceptScore W3033190176C203014093 @default.
• W3033190176 hasConceptScore W3033190176C2775915377 @default.
• W3033190176 hasConceptScore W3033190176C2776670291 @default.
• W3033190176 hasConceptScore W3033190176C2776912625 @default.
• W3033190176 hasConceptScore W3033190176C2777489490 @default.
• W3033190176 hasConceptScore W3033190176C2779075594 @default.
• W3033190176 hasConceptScore W3033190176C2779134260 @default.
• W3033190176 hasConceptScore W3033190176C2779912601 @default.
• W3033190176 hasConceptScore W3033190176C2908647359 @default.
• W3033190176 hasConceptScore W3033190176C71924100 @default.
• W3033190176 hasConceptScore W3033190176C72563966 @default.
• W3033190176 hasConceptScore W3033190176C99454951 @default.
• W3033190176 hasIssue "Suppl 1" @default.
• W3033190176 hasLocation W30331901761 @default.
• W3033190176 hasOpenAccess W3033190176 @default.
• W3033190176 hasPrimaryLocation W30331901761 @default.
• W3033190176 hasRelatedWork W1020474701 @default.
• W3033190176 hasRelatedWork W1835025283 @default.
• W3033190176 hasRelatedWork W2017224096 @default.
• W3033190176 hasRelatedWork W2074456827 @default.
• W3033190176 hasRelatedWork W2417518513 @default.
• W3033190176 hasRelatedWork W2567418569 @default.
• W3033190176 hasRelatedWork W2977585785 @default.
• W3033190176 hasRelatedWork W3171237995 @default.
• W3033190176 hasRelatedWork W4313386619 @default.
• W3033190176 hasRelatedWork W2230589347 @default.
• W3033190176 hasVolume "79" @default.
• W3033190176 isParatext "false" @default.
• W3033190176 isRetracted "false" @default.
• W3033190176 magId "3033190176" @default.
• W3033190176 workType "article" @default.